Update on the use of aromatase inhibitors in early-stage breast cancer.

Considering the hormone receptor-positive and unknown group, the difference was barely statistically significant, with 210 deaths in the exemestane arm versus 251 with tamoxifen (HR 0.83, 95% CI 0.69 to 1.00, P = 0.05).

also in 89 other papers